These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 18414463

  • 1. A patient with MEN1-associated hyperparathyroidism, responsive to cinacalcet.
    Falchetti A, Cilotti A, Vaggelli L, Masi L, Amedei A, Cioppi F, Tonelli F, Brandi ML.
    Nat Clin Pract Endocrinol Metab; 2008 Jun; 4(6):351-7. PubMed ID: 18414463
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. MEN1-related hyperparathyroidism: response to cinacalcet and its relationship with the calcium-sensing receptor gene variant Arg990Gly.
    Filopanti M, Verga U, Ermetici F, Olgiati L, Eller-Vainicher C, Corbetta S, Persani L, Beck-Peccoz P, Spada A.
    Eur J Endocrinol; 2012 Aug; 167(2):157-64. PubMed ID: 22577108
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effect of treatment with depot somatostatin analogue octreotide on primary hyperparathyroidism (PHP) in multiple endocrine neoplasia type 1 (MEN1) patients.
    Faggiano A, Tavares LB, Tauchmanova L, Milone F, Mansueto G, Ramundo V, De Caro ML, Lombardi G, De Rosa G, Colao A.
    Clin Endocrinol (Oxf); 2008 Nov; 69(5):756-62. PubMed ID: 18485119
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Acute and one-year effects of cinacalcet in patients with persistent primary hyperparathyroidism after unsuccessful parathyroidectomy.
    Iglesias P, Ais G, González A, Tajada P, García Arévalo C, Fernández Pardo E, Díez JJ.
    Am J Med Sci; 2008 Feb; 335(2):111-4. PubMed ID: 18277118
    [Abstract] [Full Text] [Related]

  • 8. Multiple endocrine neoplasia type 1 in end-stage renal failure.
    Suzuki H, Katoh T, Sakuma Y, Takahashi M, Asahi K, Hashimoto S, Kosugi S, Suzuki S, Takenoshita S, Watanabe T.
    Clin Exp Nephrol; 2004 Dec; 8(4):380-3. PubMed ID: 15619041
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism.
    Dong BJ.
    Clin Ther; 2005 Nov; 27(11):1725-51. PubMed ID: 16368445
    [Abstract] [Full Text] [Related]

  • 11. Cinacalcet (Sensipar) provides no measurable clinical benefits for patients with primary hyperparathyroidism and may accelerate bone loss with prolonged use.
    Norman J, Lopez J, Politz D.
    Ann Surg Oncol; 2012 May; 19(5):1466-71. PubMed ID: 21922336
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Elevated parathyroid hormone levels after parathyroidectomy for primary hyperparathyroidism.
    Mizrachi A, Gilat H, Bachar G, Feinmesser R, Shpitzer T.
    Head Neck; 2009 Nov; 31(11):1456-60. PubMed ID: 19405085
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Primary hyperparathyroidism in patients with multiple endocrine neoplasia type 1: comparison with sporadic parathyroid adenomas.
    Katai M, Sakurai A, Ikeo Y, Hashizume K.
    Horm Metab Res; 2001 Aug; 33(8):499-503. PubMed ID: 11544565
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Cinacalcet HCl suppresses Cyclin D1 oncogene-derived parathyroid cell proliferation in a murine model for primary hyperparathyroidism.
    Imanishi Y, Kawata T, Kenko T, Wada M, Nagano N, Miki T, Arnold A, Inaba M.
    Calcif Tissue Int; 2011 Jul; 89(1):29-35. PubMed ID: 21541686
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.